BioTime, Inc. Reports Third Quarter Results and Recent Clinical Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/26/2026
- S&P 500, Nasdaq set for weekly fall as chip stocks slide
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
- Needham Starts NeoVolta (NEOV) at Buy
- TD Cowen: 'Sober View Suggests Structural Alcohol Risks Are Overblown'
- Two major earthquakes strike Venezuela, killing at least 32 and injuring hundreds
- Hertz cuts guidance, announces notes and stock offerings, shares sink
- Wall St ends mixed as tech megacap declines outweigh upbeat chip outlook
BioTime (BTX) Posts Q3 EPS of 30c
November 4, 2016 9:20 AM EDTBioTime (NYSE: BTX) reported Q3 EPS of $0.30, which may not compare with the analyst estimate of ($0.14). Revenue for the quarter came in at $1.5 million versus the consensus estimate of $1.23 million.
Profitability was largely due to a fain on equity method investment in... More
